Featured Courses

Unmet Needs of Patients with Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 CME: Reviews the burden and unmet needs of AD, 2014 guidelines, and most recent data supporting approved and emerging therapies. Exp 10/29/22

Advancing Therapy in Moderate-to-Severe Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

1.25 CME CE: This activity focuses on incorporating new therapies for the management of moderate-to-severe Atopic Dermatitis. Exp 6/30/23

Updates in Treating Moderate-to-Severe Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

0.25 CME CE: This podcast features two dermatology specialists discussing the latest in management of moderate-to-severe AD. Exp 6/30/23

Evolving Treatments for Moderate-to-Severe Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

0.50 CME CE: New therapies are available for moderate-to-severe AD. Cases focus on decision-making from an expanding therapeutic landscape. Exp 6/30/23

Updates in Treatment of Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

1.00 CME CE: This activity addresses the challenges of prurigo nodularis and evolving therapies to manage chronic pruritus using immune-based approaches. Exp 6/30/23

Targeted Therapy in Mild-to-Moderate Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

1.00 CME CE: This activity focuses on incorporating new therapies for the management of mild to moderate Atopic Dermatitis. Exp 6/30/23

The Patient Voice: Defining Health Care Disparities in Atopic Dermatitis Care

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), ABIM MOC Points, CE for Pharmacists, ABP MOC Points

This activity will feature patient voices in addition to expert faculty discussing the implementation of best practices for diagnosing, evaluating, and treating AD among patients of color, the latest evidence on health care disparities in patients with AD and the impact of COVID-19 on the care of patients of color with AD.

The Burden of Prurigo Nodularis: New Targeted Treatments | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Prurigo nodularis results in high personal and socioeconomic costs. Targeted therapies may alleviate some of these. Learn more! Exp. 3/30/2023

Targeting Disease Mechanisms in Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Current PN therapies often do not meet treatment goals. Emerging, targeted treatment strategies are on the horizon for PN patients. Exp 3/30/23

Treating Moderate-to-Severe AD in Younger Patients | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

0.75 CME CE: Drs. Robert Sidbury and Nanette Silverberg use the case of a 2-year-old to illustrate managing pediatric patients with AD. Exp. 5/31/23

What’s New in Pediatric Atopic Dermatitis? | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

0.25 CME CE: Drs. Robert Sidbury and Nanette Silverberg discuss emerging medications, their efficacy data, and how to integrate them into practice. Exp 6/20/23

Novel Mechanisms in Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE There are limited treatment options for PN. This interactive activity provides an overview of how emerging therapies target its underlying pathophysiology. Exp 3/31/23